Literature DB >> 20501525

Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice.

S Wang1, N Yang, L Zhang, B Huang, H Tan, Y Liang, Y Li, X Yu.   

Abstract

Cytokines are known to play an important role in the pathogenesis of lupus nephritis (LN) and the Jak/STAT (Janus kinase-signal transducer and activator of transcription factor) pathway is important in mediating signal transduction of cytokines. This study examined the pathogenic role of Jak/STAT signaling in LN. MRL/lpr mice were either treated with a selective Jak2 inhibitor tyrphostin AG490 or with vehicle alone from 12 weeks of age until being sacrificed at week 20. AG490 significantly inhibited the phosphorylation of Jak2 and STAT1 (p < 0.05). Compared with the vehicle-treated mice, AG490 treatment significantly reduced proteinuria, improved renal function and suppressed histological lesions of the kidneys and salivary glands (p < 0.05). AG490 treatment significantly inhibited the renal expression of monocyte chemotactic protein (MCP)-1, interferon (IFN)-gamma and class II MHC, which was accompanied by reduced renal infiltration of T cells and macrophages (p < 0.05). In addition, AG490 treatment resulted in a decrease in serum anti-double-stranded DNA (anti-dsDNA) antibody and attenuated the deposition of IgG and C3 in the kidneys (p < 0.05). This study demonstrated that Jak/STAT pathway is implicated in the progression of renal inflammation in MRL/lpr mice and targeting this pathway may provide a potential therapeutic approach for LN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501525     DOI: 10.1177/0961203310367660

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  34 in total

1.  Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1β Pathway in Systemic Lupus Erythematosus.

Authors:  Sokha Nhek; Robert Clancy; Kristen A Lee; Nicole M Allen; Tessa J Barrett; Emanuela Marcantoni; Janet Nwaukoni; Sara Rasmussen; Maya Rubin; Jonathan D Newman; Jill P Buyon; Jeffrey S Berger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

Review 2.  Back to the future: oral targeted therapy for RA and other autoimmune diseases.

Authors:  John J O'Shea; Arian Laurence; Iain B McInnes
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

Review 3.  Type I interferon in the pathogenesis of lupus.

Authors:  Mary K Crow
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

Review 4.  The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.

Authors:  Qin Xu; Xuexiao Jin; Yu Jiang; Xin Dang; Yongmei Han
Journal:  Clin Rheumatol       Date:  2020-07-16       Impact factor: 2.980

5.  Stat1 Regulates Lupus-like Chronic Graft-versus-Host Disease Severity via Interactions with Stat3.

Authors:  Wen-Hai Shao; Ana M Gamero; Yuxuan Zhen; Monica J Lobue; Stephen O Priest; Hazem J Albandar; Philip L Cohen
Journal:  J Immunol       Date:  2015-09-21       Impact factor: 5.422

6.  Meta-analysis of MCP-1 promoter -2518 A/G polymorphism and SLE susceptibility.

Authors:  Ting Liu; Jin-Xia Zhai; Han-Yong Wang; Xing-Hua Wang; Li-Wei Zou; Wen-Jing Fan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

Review 7.  Janus kinase inhibitors in autoimmune diseases.

Authors:  John J O'Shea; Apostolos Kontzias; Kunihiro Yamaoka; Yoshiya Tanaka; Arian Laurence
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

Review 8.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

Review 9.  The role of the Janus kinase family/signal transducer and activator of transcription signaling pathway in fibrotic renal disease.

Authors:  Futoshi Matsui; Kirstan K Meldrum
Journal:  J Surg Res       Date:  2012-07-17       Impact factor: 2.192

10.  IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.

Authors:  Omar Niss; Allyson Sholl; Jack J Bleesing; David A Hildeman
Journal:  J Allergy Clin Immunol       Date:  2014-08-28       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.